- Moderna’s full-year revenue forecast is between $3 billion and $3.5 billion, down from a previous forecast of about $4 billion. The market estimate was $4.14 billion.
- Capital expenditure for the year remains steady at approximately $900 million.
- In the second quarter, Moderna reported a loss per share of $3.33.
- Second quarter revenue was $241 million, a 30% decline year-over-year, but above the market estimate of $131 million.
- Revenue from COVID-19 vaccines was $184 million, exceeding the estimate of $106 million.
- Total operating expenses in Q2 were $1.60 billion, down 27% year-over-year, and slightly below the estimate of $1.63 billion.
- Cost of goods sold totaled $115 million, a significant 84% drop year-over-year, compared to the estimate of $72.2 million.
- Research and Development (R&D) expenses amounted to $1.22 billion, higher than the estimate of $1.1 billion.
- Sales, General & Administrative (SG&A) expenses were $268 million, a 19% decrease year-over-year, and under the estimate of $307.7 million.
- Moderna expects very low sales in the European Union for 2024 based on recent tender framework agreement negotiations.
- Second quarter net product sales were $184 million, a 37% decrease year-over-year, reflecting the expected seasonal shift in COVID-19 vaccine demand.
- As of June 30, cash, cash equivalents, and investments stood at $10.8 billion, down from $12.2 billion as of March 31, 2024.
- For the second half of the year, a sales split of 40-50% is expected in the third quarter, with the remaining balance in the fourth quarter, depending on regulatory approvals.
- The update in product sales is driven by very low EU sales, potential revenue deferrals for certain international sales into 2025, and a more competitive U.S. respiratory vaccine market.
- The projected year-end cash and investments for 2024 are approximately $9 billion.
Moderna on Smartkarma
Analysts at Baptista Research have provided insightful coverage on Moderna Inc. on Smartkarma. In a report titled “Moderna Inc.: Progress in Personalized Cancer Vaccine (PCV) Manufacturing & Other Major Developments,” they highlight the company’s positive momentum in the first quarter of 2024. Moderna’s advancements in personalized cancer vaccine manufacturing and ongoing Phase III studies for COVID vaccines show promising outcomes. The company’s clinical progress on various viruses like EBV, VZV, and Norovirus further demonstrate its commitment to innovation.
In another report, “Moderna Inc: Initiation Of Coverage – Product Pipeline,” Baptista Research introduces Moderna Inc. as a leading biotechnology firm specializing in mRNA technology for therapeutics. Despite facing challenges in 2023, Moderna remained optimistic entering 2024. The company’s financial performance in 2023 revealed a revenue of $6.1 billion, with a net loss of $4.7 billion, reflecting its focus on long-term growth and innovation in the biotech sector.
A look at Moderna Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Moderna has a mixed long-term outlook. With a Value score of 3, the company seems moderately priced relative to its intrinsic value. However, Moderna lags in terms of Dividend and Growth scores, indicating a lower emphasis on these factors. Despite this, the company excels in Resilience and Momentum, with scores of 5 and 4 respectively, suggesting a strong ability to weather market fluctuations and maintain positive upward momentum.
Moderna, Inc. is a biotechnology company specializing in the development of messenger RNA therapeutics and vaccines. Their focus includes creating mRNA medicines for infectious diseases, immuno-oncology, and cardiovascular conditions. With a mix of scores across various categories, Moderna’s long-term performance may be impacted by its resilience and momentum more than its value, dividend, and growth prospects.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
